Anna Ceccarelli

Rome, 00168, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer.

Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer.

Journal: Cancer communications (London, England)

Published: January 22, 2026

Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.

Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.

Journal: Journal of translational medicine

Published: January 06, 2026

Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors.

Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors.

Journal: Journal of the National Cancer Institute

Published: December 22, 2025

Formyl peptide receptor 2 activation by MR-39 inhibits glioblastoma cell proliferation and invasiveness through suppression of multiple oncogenic pathways.

Formyl peptide receptor 2 activation by MR-39 inhibits glioblastoma cell proliferation and invasiveness through suppression of multiple oncogenic pathways.

Journal: Journal of translational medicine

Published: October 13, 2025

Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.

Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.

Journal: Journal of translational medicine

Published: September 05, 2025

Correction To: High tumor mutational burden assessed through next‑generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

Correction To: High tumor mutational burden assessed through next‑generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

Journal: Journal of translational medicine

Published: January 08, 2025

High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

Journal: Journal of translational medicine

Published: October 09, 2024

The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC).

The Impact of a Multidisciplinary Tumor Board (MDTB) in the Management of Colorectal Cancer (CRC).

Journal: Clinical colorectal cancer

Published: June 26, 2024

Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation.

Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation.

Journal: Journal of translational medicine

Published: June 26, 2024

Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance.

Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance.

Journal: Cell death & disease

Published: June 03, 2024

Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer.

Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer.

Journal: Journal of translational medicine

Published: April 29, 2024

Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.

Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.

Journal: Journal of translational medicine

Published: March 15, 2024

Showing 1-12 of 16

Last Updated: 09/26/2026